Estados Unidos · Plataformas y datos · MarketBeat
What Oncocyte (IMDX) Said on Its Q3 Earnings Call

Resumen detallado
Insight Molecular Diagnostics (IMDX) expects to respond before a January 2027 deadline to the U.S. Food and Drug Administration’s request for more information about its GraftAssureDx kidney transplant test, executives said on the company’s third-quarter earnings call. President and CEO Josh Riggs s
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)




